Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.

被引：18
|
作者：
Powles, Thomas
Choueiri, Toni K.
Burotto, Mauricio
Escudier, Bernard
Bourlon, Maria Teresa
Shah, Amishi Yogesh
Suarez, Cristina
Hamzaj, Alketa
Porta, Camillo
Hocking, Christopher
Kessler, Elizabeth R.
Gurney, Howard
Tomita, Yoshihiko
Bedke, Jens
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Apolo, Andrea B.
Motzer, Robert J.
机构：
[1] Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, England
[2] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Bradford Hill Clin Res Ctr, Santiago, Chile
[5] Gustave Roussy, Villejuif, France
[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Urol Oncol Clin, Mexico City, DF, Mexico
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Vall dHebron Barcelona Hosp Campus, Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[9] Ist Toscano Tumori, Osped San Donato, Arezzo, Italy
[10] Univ Pavia, Pavia, Italy
[11] Lyell McEwin Hosp, Elizabeth Vale, SA, Australia
[12] Univ Colorado, Canc Ctr, Anschutz Med Campus, Aurora, CO USA
[13] Westmead Hosp, Sydney, NSW, Australia
[14] Macquarie Univ Hosp, Sydney, NSW, Australia
[15] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[16] Eberhand Karls Univ Tubingen, Tubingen, Germany
[17] Bristol Myers Squibb, Princeton, NJ USA
[18] Exelixis Inc, Alameda, CA USA
[19] NCI, NIH, Bethesda, MD 20892 USA
[20] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.350
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
350
引用
收藏
页数：4
相关论文
共 47 条
  • [41] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Tannir, Nizar M.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael Anthony
    McDermott, David F.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Bracarda, Sergio
    Tykodi, Scott S.
    Powles, Thomas
    Rini, Brian I.
    Tomita, Yoshihiko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [42] Association Between Depth of Response (DepOR) and Overall Survival (OS): Exploratory Analysis of Nivolumab plus Ipilimumab (N plus I) vs Sunitinib (S) in Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) in Checkmate 214
    Gruenwald, Viktor
    Choueiri, Toni K.
    Rini, Brian I.
    Powles, Thomas
    George, Saby
    Grimm, Marc-Oliver
    Mchenry, M. Brent
    Maurer, Matthew
    Motzer, Robert J.
    Hammers, Hans J.
    Tannir, Nizar M.
    Albiges, Laurence
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 74 - 75
  • [43] Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
    Haanen, J. B. A. G.
    Larkin, J.
    Choueiri, T. K.
    Albiges, L.
    Rini, B. I.
    Atkins, M. B.
    Schmidinger, M.
    Penkov, K.
    Michelon, E.
    Wang, J.
    Mariani, M.
    di Pietro, A.
    Motzer, R. J.
    ESMO OPEN, 2023, 8 (03)
  • [44] Dual immune checkpoint inhibition in metastatic renal cell carcinoma Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
    Schmidinger, M.
    Shariat, S. F.
    Fajkovic, H.
    ESMO OPEN, 2021, 6 (01)
  • [45] Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.
    Tannir, Nizar M.
    Signoretti, Sabina
    Choueiri, Toni K.
    McDermott, David F.
    Motzer, Robert J.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Tykodi, Scott S.
    Pal, Sumanta K.
    Gupta, Saurabh
    Lee, Chung-Wei
    McHenry, M. Brent
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [46] LIFETIME SURVIVAL ESTIMATES FOR NIVOLUMAB plus IPILIMUMAB AND SUNITINIB IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED/METASTATIC INTERMEDIATE- OR POOR (I/P)-RISK RENAL CELL CARCINOMA (1L ARCC) BASED ON 5-YEAR MINIMUM FOLLOW-UP DATA FROM CHECKMATE 214
    Qendri, V
    May, J. R.
    Ejzykowicz, F.
    Kurt, M.
    Cakar, E.
    Klijn, S.
    VALUE IN HEALTH, 2022, 25 (01) : S24 - S24
  • [47] Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (vol 8, e000891, 2020)
    Motzer, R. J.
    Escudier, B.
    McDermott, D. F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (05)
12345